2021 Form 10-K Financial Statement
#000121390022010573 Filed on March 03, 2022
Income Statement
| Concept | 2021 | 2020 Q4 | 2020 |
|---|---|---|---|
| Revenue | $181.0K | $10.00K | $10.00K |
| YoY Change | 1710.0% | ||
| Cost Of Revenue | |||
| YoY Change | |||
| Gross Profit | |||
| YoY Change | |||
| Gross Profit Margin | |||
| Selling, General & Admin | $8.791M | $1.360M | $6.320M |
| YoY Change | 39.1% | -7.48% | 4.98% |
| % of Gross Profit | |||
| Research & Development | $20.54M | $1.860M | $5.920M |
| YoY Change | 247.01% | 113.79% | 80.49% |
| % of Gross Profit | |||
| Depreciation & Amortization | |||
| YoY Change | |||
| % of Gross Profit | |||
| Operating Expenses | $29.33M | $3.220M | $12.24M |
| YoY Change | 139.66% | 38.2% | 57.73% |
| Operating Profit | -$29.15M | ||
| YoY Change | |||
| Interest Expense | -$985.0K | ||
| YoY Change | |||
| % of Operating Profit | |||
| Other Income/Expense, Net | -$202.0K | $0.00 | $130.0K |
| YoY Change | -255.38% | ||
| Pretax Income | -$30.34M | -$3.200M | -$12.10M |
| YoY Change | 150.74% | 37.93% | 57.55% |
| Income Tax | |||
| % Of Pretax Income | |||
| Net Earnings | -$30.34M | -$3.200M | -$12.10M |
| YoY Change | 150.74% | 37.93% | 57.55% |
| Net Earnings / Revenue | -16762.43% | -32000.0% | -121000.0% |
| Basic Earnings Per Share | -$1.88 | ||
| Diluted Earnings Per Share | -$1.881M | -$237.7K | -$1.009M |
| COMMON SHARES | |||
| Basic Shares Outstanding | 16.13M shares | ||
| Diluted Shares Outstanding | 16.13M shares |
Balance Sheet
| Concept | 2021 | 2020 Q4 | 2020 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $74.81M | $21.97M | $21.97M |
| YoY Change | 240.51% | 213.86% | 213.86% |
| Cash & Equivalents | $74.81M | $21.97M | $21.97M |
| Short-Term Investments | |||
| Other Short-Term Assets | $2.292M | $220.0K | $220.0K |
| YoY Change | 941.82% | 83.33% | 83.33% |
| Inventory | |||
| Prepaid Expenses | |||
| Receivables | |||
| Other Receivables | |||
| Total Short-Term Assets | $82.61M | $23.99M | $23.99M |
| YoY Change | 244.34% | 209.15% | 209.15% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $726.0K | $160.0K | $160.0K |
| YoY Change | 353.75% | -15.79% | -15.79% |
| Goodwill | |||
| YoY Change | |||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | $99.00K | ||
| YoY Change | |||
| Total Long-Term Assets | $17.34M | $16.67M | $16.67M |
| YoY Change | 4.01% | -0.24% | -0.24% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $82.61M | $23.99M | $23.99M |
| Total Long-Term Assets | $17.34M | $16.67M | $16.67M |
| Total Assets | $99.95M | $40.66M | $40.66M |
| YoY Change | 145.81% | 66.16% | 66.16% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $3.813M | $1.550M | $1.550M |
| YoY Change | 146.0% | 124.64% | 124.64% |
| Accrued Expenses | $72.00K | $30.00K | $30.00K |
| YoY Change | 140.0% | 200.0% | 200.0% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | |||
| YoY Change | |||
| Total Short-Term Liabilities | $4.359M | $1.780M | $1.780M |
| YoY Change | 144.89% | 154.29% | 154.29% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $14.46M | $0.00 | $0.00 |
| YoY Change | |||
| Other Long-Term Liabilities | $903.0K | $130.0K | $130.0K |
| YoY Change | 594.62% | -18.75% | -18.75% |
| Total Long-Term Liabilities | $15.36M | $130.0K | $130.0K |
| YoY Change | 11716.15% | -18.75% | -18.75% |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $4.359M | $1.780M | $1.780M |
| Total Long-Term Liabilities | $15.36M | $130.0K | $130.0K |
| Total Liabilities | $19.72M | $1.900M | $1.900M |
| YoY Change | 937.89% | 120.93% | 120.93% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | |||
| YoY Change | |||
| Common Stock | |||
| YoY Change | |||
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $80.23M | $38.75M | $38.75M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $99.95M | $40.66M | $40.66M |
| YoY Change | 145.81% | 66.16% | 66.16% |
Cashflow Statement
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2021 | dei |
Entity Registrant Name
EntityRegistrantName
|
Inmune Bio, Inc. | |
| CY2021 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001711754 | |
| CY2021Q2 | dei |
Entity Public Float
EntityPublicFloat
|
157000000 | USD |
| CY2020Q4 | inmb |
Prepaid Expenses Related Party
PrepaidExpensesRelatedParty
|
USD | |
| CY2020Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
USD | |
| CY2020Q4 | us-gaap |
Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
|
USD | |
| CY2020Q4 | us-gaap |
Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
|
USD | |
| CY2021Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
| CY2020Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
| CY2021Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
USD | |
| CY2020Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
USD | |
| CY2020 | inmb |
Cashless Exercise Of Warrant
CashlessExerciseOfWarrant
|
USD | |
| CY2020 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
USD | |
| CY2020 | us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
USD | |
| CY2020 | us-gaap |
Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
|
USD | |
| CY2020 | us-gaap |
Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
|
USD | |
| CY2020 | inmb |
Cash Paid To Xencor To Settle Warrant For Acquired Research And Development Intangible Assets
CashPaidToXencorToSettleWarrantForAcquiredResearchAndDevelopmentIntangibleAssets
|
USD | |
| CY2020 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
USD | |
| CY2020 | us-gaap |
Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
|
USD | |
| CY2020 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
USD | |
| CY2020 | us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
USD | |
| CY2021 | us-gaap |
Origination Of Loan To Purchase Common Stock
OriginationOfLoanToPurchaseCommonStock
|
USD | |
| CY2020 | us-gaap |
Interest Paid Net
InterestPaidNet
|
USD | |
| CY2020 | inmb |
Common Stock Issued To Xencor To Settle Warrant Issued For Acquired Research And Development I
CommonStockIssuedToXencorToSettleWarrantIssuedForAcquiredResearchAndDevelopmentI
|
USD | |
| CY2020 | inmb |
Noncash Or Part Noncash Issuance Of Warrants To Placement Agents
NoncashOrPartNoncashIssuanceOfWarrantsToPlacementAgents
|
USD | |
| CY2021 | inmb |
Stock Issued During Period Shares Capital Contribution
StockIssuedDuringPeriodSharesCapitalContribution
|
USD | |
| CY2021 | inmb |
Issuance Of Common Stock Issuable
IssuanceOfCommonStockIssuable
|
USD | |
| CY2021Q4 | inmb |
Less Current Portion
LessCurrentPortion
|
USD | |
| CY2021Q4 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Rolling Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo
|
USD | |
| CY2020 | inmb |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercised
|
shares | |
| CY2020 | inmb |
Options Exercised
OptionsExercised
|
USD | |
| CY2020 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
|
shares | |
| CY2020 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
||
| CY2020 | inmb |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term Exercisable
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermExercisable
|
||
| CY2020Q4 | inmb |
Aggregate Intrinsic Value Options Cancelled
AggregateIntrinsicValueOptionsCancelled
|
USD | |
| CY2021 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
|
shares | |
| CY2021 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
||
| CY2021 | inmb |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term Exercisable
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermExercisable
|
||
| CY2021Q4 | inmb |
Aggregate Intrinsic Value Options Cancelled
AggregateIntrinsicValueOptionsCancelled
|
USD | |
| CY2021 | us-gaap |
Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
|
USD | |
| CY2020 | us-gaap |
Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
|
USD | |
| CY2021 | us-gaap |
Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
|
USD | |
| CY2020 | us-gaap |
Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
|
USD | |
| CY2021 | us-gaap |
Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
|
USD | |
| CY2020 | us-gaap |
Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
|
USD | |
| CY2021 | us-gaap |
Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
|
USD | |
| CY2020 | us-gaap |
Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
|
USD | |
| CY2021 | us-gaap |
Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
|
USD | |
| CY2020 | us-gaap |
Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
|
USD | |
| CY2021 | us-gaap |
Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
|
USD | |
| CY2020 | us-gaap |
Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
|
USD | |
| CY2021Q4 | us-gaap |
Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
|
USD | |
| CY2020Q4 | us-gaap |
Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
|
USD | |
| CY2021 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
USD | |
| CY2020 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
USD | |
| CY2021Q4 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
USD | |
| CY2020Q4 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
USD |
